Search company, investor...

AHEAD Medicine

aheadmedicine.com

Stage

Convertible Note | Alive

Total Raised

$110K

Last Raised

$110K | 2 yrs ago

About AHEAD Medicine

AHEAD Medicine develops an AI-based flow cytometry analysis platform that enables reduction of exam turnaround time and timely access to life-saving therapies. AHEAD-flow uses artificial intelligence to automatically analyze the immunophenotype of specimens and detect abnormalities on clinical flow cytometry data 100 times faster than traditional manual analysis.

Headquarters Location

2150 Shattuck Ave Penthouse

Berkeley, California, 94704,

United States

Missing: AHEAD Medicine's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AHEAD Medicine's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AHEAD Medicine

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AHEAD Medicine is included in 1 Expert Collection, including Digital Health.

D

Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest AHEAD Medicine News

23:05 EDT Taiwan Firm AHEAD Medicine Disrupting cell analysis with AI to help accelerate disease diagnostics and cell therapy wo...

Jul 29, 2022

News provided by Share this article Share this article AHEAD Medicine's AI platform removes bottlenecks in drug discovery, clinical trials, and patient treatment, increasing speed, accuracy, and reproducibility. TAIPEI, July 28, 2022 /PRNewswire/ -- AHEAD Medicine, a UC Berkeley SkyDeck-backed company has launched a new AI-enabled cell immuno-profiling analysis platform. The platform unlocks the cell-level data critical to vaccine, therapeutic research & development, patient diagnosis, and the safety of next generation treatments like cell therapy, the company will be showcasing its technology at US bio 2022. Your 37 trillion cells hold secrets to your health. Hospitals and labs use machines called flow cytometers to investigate your cells size, shape, age and protein expression. Currently, turning this cell-level data into actionable clinical insights is manual, requiring highly trained humans to visually interpret millions of data points at a time. As a result, it is an expensive, error prone bottleneck in advanced healthcare markets and simply unavailable in emerging markets. AHEAD's AI platform delivers instant results, improves interpretation accuracy and repeatability at substantial cost savings. Andrea Wang, CEO and co-founder of AHEAD Medicine, a cancer survivor with graduate experience in cancer research and data science, has always had a keen interest in applying AI to medicine. Speaking about the company's core technology, Wang shares, "we have developed a fully-automated analysis software platform where physicians or researchers simply upload raw cell analysis data from flow cytometry instruments. Our software instantly analyzes multiple specimens simultaneously, delivering actionable insights in seconds." Roots in STEM haven Taiwan Taiwan boasts of a sizable pool of high-quality STEM talent, extensive expertise and a productive environment for conducting clinical trials, advanced bio-ICT capacity, and active government-industry-academia cooperation in medical research. AHEAD is a product of this system. Research teams from National Taiwan University Hospital and National Tsing Hua University with the support of the Ministry of Science and Technology (MOST), developed and eventually spun off the technology behind AHEAD Medicine and its Taiwanese R&D subsidiary AHEAD Intelligence. The startup boasts a broad patent portfolio based on this collaboration. From Taiwan to the rest of the world AHEAD Medicine is currently expanding globally, with a new US Headquarters opened in California, and it's first RUO product available for acute leukemia and lymphoma. With easy-to-use software that improves the efficiently, accuracy and reproducibility of cellular analysis, AHEAD is on its way to bringing next generation science and treatment to everyone. AHEAD Medicine Disrupting cell analysis with AI to help accelerate disease diagnostics and cell therapy worldwide To learn more, visit https://www.aheadmedicine.com SOURCE AHEAD Medicine AHEAD Intelligence ×

AHEAD Medicine Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AHEAD Medicine Rank

AHEAD Medicine Frequently Asked Questions (FAQ)

  • Where is AHEAD Medicine's headquarters?

    AHEAD Medicine's headquarters is located at 2150 Shattuck Ave Penthouse, Berkeley.

  • What is AHEAD Medicine's latest funding round?

    AHEAD Medicine's latest funding round is Convertible Note.

  • How much did AHEAD Medicine raise?

    AHEAD Medicine raised a total of $110K.

  • Who are the investors of AHEAD Medicine?

    Investors of AHEAD Medicine include Berkeley SkyDeck.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.